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Diabetic patients treated with metformin have a reduced incidence of cancer and cancer-
related mortality. Here we show that metformin affects engraftment and growth of breast 
cancer tumours in mice. This correlates with the induction of metabolic changes compatible 
with clear anticancer effects. We demonstrate that microRnA modulation underlies the 
anticancer metabolic actions of metformin. In fact, metformin induces DICER expression and 
its effects are severely impaired in DICER knocked down cells. Conversely, ectopic expression 
of DICER recapitulates the effects of metformin in vivo and in vitro. The microRnAs upregulated 
by metformin belong mainly to energy metabolism pathways. Among the messenger RnAs 
downregulated by metformin, we found c-mYC, IRs-2 and HIF1alpha. Downregulation of 
c-mYC requires AmP-activated protein kinase-signalling and mir33a upregulation by metformin. 
Ectopic expression of c-mYC attenuates the anticancer metabolic effects of metformin. We 
suggest that DICER modulation, mir33a upregulation and c-mYC targeting have an important 
role in the anticancer metabolic effects of metformin. 
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Altered metabolism is a key feature of cancer cells. It drives the cells towards a pro-proliferative anabolic phase rather than efficient ATP production. A distinct trait of the can-
cer metabolism is the unscheduled activation of glycolytic enzymes 
in normoxic conditions, indicated by increased cellular glucose 
uptake, hyper-glycolysis and lactate1–3. This represents a mecha-
nism of neoplastic progression. Indeed, known oncogenes alter 
cell metabolism through modulation of key glycolytic enzymes4–9. 
Metformin (1,1–dimethylbiguanide hydrochloride) is a widely used 
antidiabetic agent that decreases insulin resistance and lowers blood 
glucose levels through the inhibition of liver glucose production and 
an increased glucose uptake in muscles10,11.
Multiple epidemiological studies show that diabetic patients 
treated with metformin have reduced incidence of cancer and 
reduced cancer mortality12. In addition, metformin affects the 
progression and relapse of breast, prostate and lung cancer mouse 
xenografts, when combined with suboptimal doses of standard 
chemotherapeutic agents13–16. Metformin activates the AMP- 
activated protein kinase (AMPK)17,18, a major sensor of the 
energetic status of the cell19. Activation of AMPK inhibits mam-
malian target of rapamycin (mTOR) signalling20 and stimulates the 
p53/p21 axis21 potentially affecting p53 downstream targets22. Hence, 
metformin combines both metabolic and anticancer properties. 
Additionally, the anticancer activity of metformin on tumour 
xenografts highly differing in their tissue of origin, oncogene 
expression and p53 status23,24 suggests the existence of a broader 
mechanism of action for this drug.
MicroRNAs are short, stable, noncoding RNAs that target the 
mRNA of coding genes for degradation, thus effectively reducing 
the levels of the gene products. MicroRNA modulation represents 
an effective strategy through which external stimuli can rapidly 
alter the cell and tissue homeostasis, by targeting multiple genes 
at the same time. The RNAse III DICER has a role in processing 
double-stranded RNA to short interfering RNA (siRNA) and in the 
assembly of the siRNA into the machinery that targets the mRNAs 
for degradation25. In fact, the expression of DICER directly influ-
ences the biosynthesis of all microRNAs, thereby severely affecting 
gene expression patterns26. Interestingly, downregulation of the 
DICER levels was shown to represent an intrinsically oncogenic 
event, by enhancing epithelial to mesenchymal transition and 
metastatic dissemination of breast cancer cells27. Furthermore, low 
expression of DICER predicted poor survival of breast, lung and 
ovarian cancer patients28,29.
Given the potential ability of metformin to broadly affect 
multiple pathways, we hypothesized that microRNA modula-
tion could be part of its mechanism of action. By using xenograft 
transplantation experiments, hydrogen-(1H) nuclear magnetic 
resonance (1H-NMR)-based metabolic analysis and microRNA 
profiling, we demonstrated that microRNA modulation underlies 
the anticancer metabolic actions of metformin. Metformin modu-
lated microRNA by transcriptionally activating the promoter of 
DICER. Metformin-modulated microRNAs were predicted to 
impinge mainly on the energy metabolism and insulin signalling 
pathways. In addition, we show that metformin affects the mRNA 
levels of c-MYC, IRS-2 and HIF1alpha as well. The sequential 
modulation of DICER, microRNA-33a and of c-MYC levels may 
partially explain the anticancer metabolic effects of metformin.
Results
Metformin inhibits tumour engraftment and growth. We 
performed experiments aimed at evaluating the effect of metformin 
on breast cancer xenografts. For this, we used a basal-like, triple-
negative breast cancer cell line (SUM159PT)30 and evaluated 
the effects of metformin in three different experimental settings 
(Fig. 1). First, we studied the frequency of tumour engraftment 
in metformin-pretreated mice. 1 week before cell transplantation, 
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Figure 1 | Anticancer properties of metformin. (a) Tumour volume of CD1 mice treated with vehicle or metformin (16 mg kg − 1, bi-weekly) before 
subcutaneous transplantation of sum159PT cells (1×106 cells per mouse, n = 7). (b) survival curve of the CD1 mice (n = 7) as from the experiment in (a). 
Log-rank test used to compare survival curves (P < 0.05). (c) Tumour re-engraftment assay. Briefly, tumours (n = 2 per group) excised from the mice as 
from (a) (first transplant) were disaggregated and transplanted into untreated secondary recipient mice (second transplant, n = 7). Histograms show the 
percentage of re-engrafted tumours in untreated recipients. (d) Tumour volume of mice (n = 6) treated with doxorubicin (4 mg kg − 1- for 4 *5dd cycles) or 
metformin (16 mg kg − 1, biweekly) when the average starting tumour volume was 0.2 cm3. (e) Representative micrographs of the excised tumours at day 
60 p.i. scale bar, 100 µm. (f) Histograms show the percentage of positive cells from four tumours per group. mean ± s.d. values represent the average of 
three independent experiments statistics: P < 0.05 by student’s t-test. ns, not significant.
ARTICLE 

nATuRE CommunICATIons | DoI: 10.1038/ncomms1859
nATuRE CommunICATIons | 3:865 | DoI: 10.1038/ncomms1859 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
mice (n = 7) were treated intraperitoneally with either metformin 
(16 mg kg − 1) or vehicle (Fig. 1a) and metformin treatment restarted 
72 h after cell implantation up to the termination of the study 
(day 121). The tumour engraftment in mice pretreated with metformin 
was significantly reduced (6/7 and 2/7 engrafted tumours for 
vehicle- and metformin-treated mice, respectively, P < 0.05; Fig. 
1a). A clear effect of metformin on the survival of tumour-bearing 
mice was observed as well (Fig. 1b). Second, to study the effect 
on tumour incidence, we evaluated the impact of metformin on 
tumour re-engraftment. In short, tumours collected from either 
treated or untreated mice (as from 1a,b) were enzymatically 
digested and re-transplanted into new untreated-recipient hosts 
(n = 7). This revealed that the engraftment rate of the tumours 
excised from metformin-treated donors was considerably reduced, 
as compared with that of the tumours derived from vehicle-treated 
donors (7/7 and 3/7 engrafted tumours for vehicle- and metformin-
treated mice, respectively, P < 0.05; Fig. 1c). Third, we evaluated 
the effect of metformin (16 mg kg − 1, bi-weekly) in comparison 
to that of doxorubicin (4 mg kg − 1, weekly) on already established 
tumours (starting volume ± 0.2 cm3) (Fig. 1d). This showed that 
metformin-treated mice had smaller tumours than vehicle-treated 
mice (0.85 ± 0.09 cm3 vs 2,33 ± 0.24 cm3, at day 60 p.i., respectively) 
and that metformin-treatment affected tumour volume to a 
degree comparable to doxorubicin treatment (0.85 ± 0.09 cm3 vs 
1.20 ± 0.09 cm3 at day 60 post cell injection, respectively). Finally, the 
proliferative index of tumours derived from metformin-treated mice 
was much lower than that of control mice (Fig. 1e,f). Interestingly, 
no toxicity was observed in mice treated with metformin (Fig. 1b).
Metformin has anticancer metabolic effects. We then used 
1H-NMR spectroscopy31–33 to characterize the metabolic effects of 
metformin. In short, we collected the NMR spectra of drug- and 
vehicle-treated samples from tumour tissue extracts (Fig. 2a–c) and 
the data were organized according to a principal component analy-
sis (PCA) model, an unsupervised method allowing orthogonal 
decomposition of variance associated with the analysed metabo-
lites34. This revealed that the metabolic effects of metformin were 
different from those exerted by doxorubicin treatment (Fig. 2a; Sup-
plementary Table S1). More in detail, the orthogonal projections to 
latent structures-discriminant analysis (OPLS-DA)35 (that excludes 
from the analysis the background metabolic effects not due to 
metformin) revealed that vehicle- and metformin-treated tumour 
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Figure 2 | Metabolic effects of metformin. (a–c) 1H-nmR determination of the metabolites of the excised tumours from vehicle-, doxorubicin- or 
metformin-treated mice. nmR data were organized according to a principal component analysis (PCA) model. metabolite clustering identifies pathways 
(KEGG) and the association of metabolites with vehicle- or metformin-treated samples (empty symbols vs filled symbols, respectively) indicates pathway 
engagement. In (b), an oPLs-DA analysis was used to minimize the effect of the background signal in the excised tumours. (c) Histograms indicate the 
relative levels of the main metabolites considered in the score/loading plots in (b) (d–f) 1H-nmR determination of the metabolites from in vitro cultured 
sum159PT cells. (d) PCA score/loading plots for the intracellular metabolites of vehicle and metformin-treated cells. (e) PCA-score/loading plots for 
the extracellular metabolites of vehicle and metformin-treated cells. (f) Histograms showing the relative levels of the main metabolites considered in 
(d). (f) inset: relative levels of glucose-derived lactate from sum159PT cells labelled with [1,2-13C2]-glucose. Data represent mean ± s.d. values of at 
least three independent experiments. statistics: P < 0.05. ns, not significant. Ala, alanine; Glu, glutamate; Pyr, pyruvate; GsH, glutathione, Glc, glucose; 
Phe, phenylalanine; u(T,D,m)P + uDP-glc, uridine triphosphate, diphosphate and monophosphate  +  uridine diphosphate glucose; C(T,D) + G(T,D,m)P, 
cytidine triphosphate and diphosphate  +  guanosine triphosphate, diphosphate and monophosphate; AmP, adenosine monophosphate; PtCho, 
phosphatidylcholine; PtEn, phosphatidyl-ethanolamine; Ps, serine phospholipids; sPH, sphingomyelin.
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samples were significantly different on the first component (t0), 
which describes the funnelling of glucose, glutamate and pyruvate 
to sustain energy production (Fig. 2b). Therefore, the metformin-
treated tumours bore significant differences in the way glucose is 
used and how carbon (from glucose) is funnelled through the central 
carbon metabolism (Glycolysis, the pentose phosphate pathway and 
the TCA cycle). Specifically, our analysis showed a reduced utiliza-
tion of the pentose-phosphate-pathway for the nucleotide synthesis 
in metformin-treated tumours (Fig 2c). We observed a perturba-
tion of phospholipid and sphingolipid metabolism: with a signifi-
cantly higher glycerophosphocholine to phosphocholine (GPC to 
PC) ratio in metformin-treated tumours (1.10 ± 0.06 and 0.76 ± 0.17 
for metformin and vehicle-treated mice, respectively, P < 0.02; Fig. 
2c). Interestingly, a higher GPC to PC ratio is a feature of non-
tumour cells36,37. Overall, the in vivo analysis suggested a shift 
from a mainly anabolic to a more catabolic utilization of glucose- 
derived carbon in metformin-treated cells. We provided a more 
detailed characterization of the metabolic fluxes modulated by met-
formin by analysing the changes of intracellular and extracellular 
metabolites in in vitro cultured SUM159PT cells (Fig. 2d–f). Cells 
were exposed to concentrations of metformin (0.5 mM) that did not 
cause any measurable cytotoxic effect, while promoting activation 
of the AMPK pathway (Supplementary Fig. S1). A statistically sig-
nificant separation between the two groups of samples was observed 
on the PC1 (P < 0.001; Fig. 2d). Analysis of the loading plots on 
the PC1 revealed that, as compared with vehicle-treated cells, 
metformin-treated cells showed higher levels of branched-chain 
amino acids, lactate, glutamine, glutamate, pyruvate, glycine, glu-
tathione, taurine, myo-inositol, creatine, glycerophosphocholine, 
phosphatidyl-choline, phosphatidyl-ethanolamine and AMP 
(positive correlation with PC1) as well as lower levels of alanine, 
aspartate, formate, phosphocreatine and nucleotides (negative cor-
relation with PC1, Fig. 2d, f). High levels of AMP in the metformin-
treated samples indicated a decreased ATP/AMP ratio, which may 
highlight AMPK activation (Fig. 2f). In line with this, we observed 
increased levels of creatine and reduced levels of phosphocreatine 
in the treated cells, consistent with a decreased storage of intra-
cellular ATP (Fig. 2f). The in vitro analysis indicated a decreased 
ATP storage and a reduced de novo nucleotide synthesis. We then 
analysed the NMR spectra of conditioned media from vehicle- and 
metformin-treated SUM159PT cells (Fig. 2e). The analysis of the 
metabolite loadings revealed that metformin treatment induced 
higher consumption of branched-chain amino acids, glutamine, 
glutamate, succinate, aspartate, glucose, tyrosine and phenylalanine 
as well as a lower production of ketoacids (2-OMV and 2-OIV) 
(Fig. 2e). As 2-OMV and 2-OIV are catabolic intermediates of the 
branched-chain amino acids, this indicated that the treated cells 
convert preferentially isoleucine and valine to succinyl-CoA. This 
suggested that metformin-treated cells use amino acids for energy 
production, instead of macromolecule biosynthesis. In summary, 
the in vitro data suggested a reversion from anabolic to catabolic 
metabolism, thus recapitulating what previously observed in vivo. 
Interestingly, the combined analysis of the extracellular and intra-
cellular metabolites showed that metformin-treated cells took up 
more glucose and produced more lactate. However, a lower flux of 
metabolites through the glycolysis in metformin-treated samples 
was observed (Fig. 2d–e). This was confirmed by the NMR analysis 
with [1,2-13C2]-glucose, showing that the levels of glucose-derived 
lactate were lower in metformin-treated samples as compared 
with vehicle-treated cells (Fig. 2f, inset). Therefore, in the treated 
cells, glucose was used mainly for catabolic purposes rather than 
for nucleotide biosynthesis. Interestingly, metformin treatment 
affected similarly the metabolic profile of two unrelated breast 
cancer cell lines (MCF-7 and BT-474), with the strongest effect 
observed for MCF7 cells on the PC2. PC2 (0.06 for SUM159PT, 
0.45 for MCF-7, and 0.27 for BT-474- Supplementary Fig. S2a; 
Supplementary Table S2). We observed no significant effect of the 
drug on the metabolic activity of MCF10A cells (untransformed, 
dysplastic breast cells)38 (Supplementary Fig. S2a; Supplementary 
Table S2). This correlated with the absence of toxic effects observed 
in metformin-treated mice (Fig. 1b).
Metformin modulates microRNAs. To investigate which mecha-
nisms could underlie the observed effects of metformin, we studied 
the microRNA expression of vehicle- and metformin-treated breast 
cancer cells, by using the same experimental conditions used for the 
metabolic profiling (Fig. 2d-f). Metformin treatment affected micro-
RNA expression of all the breast cancer cell lines tested, with no 
statistically significant modulation only in the dysplastic MCF10A 
cells (ANOVA analysis, P < 0.05; Supplementary Fig. S2b). A more 
detailed analysis of the SUM159PT cells treated with metformin 
revealed a change of the overall microRNA levels (Fig. 3a; Supple-
mentary data 1) that was attenuated in those cells stably infected with 
DICER-targeting short hairpin RNAs (shRNAs)(referred as DICER 
k/d cells in Fig. 3b). As expected, DICER depletion did not seem to 
affect microRNAs, whose levels were low at steady state (Fig 3b). 
Among the microRNAs upregulated by metformin in SUM159PT 
cells, two different groups (regions A and B) could be observed, 
based on their apparent sensitivity to DICER depletion (Fig. 3a,b). 
We focussed on the microRNAs upregulated by metformin in the 
region A of the clustergram, which showed the highest level of sen-
sitivity to DICER depletion (Fig. 3b). In silico prediction analysis 
revealed that the microRNAs in the selected region mostly tar-
geted genes involved in metabolism and insulin signalling (Fig. 3c), 
thus establishing a link between the microRNA modulation and the 
metabolic action of the drug.
Metformin modulates the levels of DICER. To understand how 
metformin could modulate the levels of the intracellular micro-
RNAs, we evaluated the effect of metformin on the RNASE III 
endonuclease DICER, one of the key enzymes of microRNA 
biogenesis26. We found that treatment of SUM159PT cells with 
metformin for 24 h led to a significant increase in DICER pro-
tein levels (Fig. 4a) that correlated with increased mRNA levels of 
DICER (Fig. 4b). Two other known AMPK activators (phenformin 
and AICAR) affected DICER levels as well (Fig. 4c). A computer-
assisted analysis of the DICER promoter (promoter 1) revealed the 
presence of multiple E2F DNA-binding sites within 1 kb from the 
transcription start site (Fig. 4d). We hypothesized that metformin 
could influence the activity of the E2F transcription factors on the 
DICER promoter. To this end, we performed chromatin immuno-
precipitation experiments aimed at evaluating promoter occupancy 
by E2F transcription factors in the treated cells. This showed that 
metformin treatment triggered an increased binding of the tran-
scriptional activator E2F3 while promoting a decrease of the tran-
scriptional repressor E2F5 at the DICER promoter (Fig. 4d–e). 
Additionally, the presence of the hyper-acetylated histone H4, of 
the histone acetyl-transferase p300 and of the elongating form of 
Pol-II (pol-II phospho-CTDser2) was increased at the E2F binding 
sites in the treated cells, indicating transcriptional activation of the 
promoter by metformin (Fig. 4f). To confirm the role of the E2Fs 
in mediating the increase of DICER in metformin-treated cells, 
we depleted by siRNA the E2F1/E2F3 in 293 cells and this affected 
the induction of DICER mRNA by metformin (Fig. 4g). Con-
versely, the overexpression of E2F1 and E2F3 triggered an induction 
of DICER mRNA compatible with that observed on metformin 
treatment (Fig. 4h).
DICER is required for the anticancer action of metformin. To 
study the functional relevance of DICER modulation for the anti-
cancer effects of metformin, we evaluated the effect of the drug on 
the tumorigenic properties of control (scrambled-shRNA)- and 
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DICER k/d SUM159PT cells (Fig. 5a). This revealed that metformin 
treatment affected both colony-forming ability and wound-heal-
ing closure of control cells, thus pairing the observed effect on the 
engraftment of newly formed tumours and that these effects were 
strongly attenuated in DICER k/d cells (Fig 5b-c, Supplementary 
Fig. S4a,b). Notably, the ectopic expression of an RNAi-resistant 
DICER mRNA affected the clonogenicity and the migration 
of SUM159PT cells in a way similar to metformin treatment 
(Fig. 5b–c). Next, we compared the effect of metformin and that of 
the ectopic expression of the RNAi-resistant DICER on the engraft-
ment of control- and DICER k/d cells. The in vivo study revealed 
that metformin affected tumour engraftment in control cells and was 
unable to do so in DICER k/d cells (2/6 vs 5/6 engrafted tumours/
injected mice in metformin-treated control and DICER k/d cells, 
respectively; Fig. 5d). Additionally, the overexpression of the RNAi-
stable DICER in both control and DICER k/d cells affected the 
tumour engraftment in a way comparable to the metformin treat-
ment (Fig. 5d). Finally, we evaluated whether the ectopic expres-
sion of RNAi-stable DICER could rescue the effect of metformin 
on the DICER k/d cells. The overexpression of the RNAi-resistant 
DICER in DICER k/d cells affected the metabolic profile of the cells 
with major changes on the PC1 (Fig. 5e; Supplementary Table S3). 
Moreover, metformin treatment triggered stronger metabolic 
changes on the PC1 in the DICER k/d cells transfected with the 
RNAi-resistant DICER, as compared with those transfected with 
the empty-vector (P = 0.001 vs 0.01, respectively (Fig. 5e; Supple-
mentary Table S3)). Thus, both ectopic expression of DICER and 
metformin treatment perturbed similar metabolic components 
and showed synergistic effects on the PC1 (Fig. 5e; Supplementary 
Table S3). This correlated with the observation that many met-
formin-modulated microRNAs target energy metabolism pathways 
(Fig. 3c). In summary, ectopic expression of DICER mimicked, to 
a considerable extent, the effect of metformin in terms of meta-
bolic modulation, tumour engraftment, colony-forming ability and 
wound-healing inhibition.
Metformin modulates c-MYC levels via mir-33a. Among the met-
formin-regulated microRNAs, we focussed on the microRNA-33a 
owing to its robust modulation by metformin (~4-folds-log2- over 
vehicle-treated cells, Supplementary data 1, bold), its predicted 
binding to the c-MYC-UTR region (position 80–86 in the inset of 
Fig. 6a), and its involvement into the modulation of IRS2 levels39. 
Quantitative PCR (qPCR) revealed that metformin and two 
other AMPK activators (phenformin and AICAR) altered the 
microRNA-33a levels and this was abolished in DICER k/d cells 
(Fig. 6a). Upregulation of mir-33a by metformin paired with a 
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downregulation of the 3′UTR activity of the c-MYC mRNA, which 
was specifically antagonized by a mir33a antagonist (Fig. 6b). Con-
sequently, metformin significantly downregulated the endogenous 
c-MYC mRNA and protein levels in a DICER-dependent way 
(Fig. 6c-d, upper panel).
Modulation of c-MYC mediates the metabolic effect of met-
formin. Finally, we tested whether the ectopic expression of c-MYC 
could counteract the metabolic effects of metformin. To this end, 
we stably transfected SUM159PT cells with either empty- or c-MYC-
expressing vectors and treated them with vehicle or metformin 
(Fig. 6d). The analysis of the extracellular metabolites revealed that, in 
c-MYC-overexpressing cells, the effect of metformin was significantly 
attenuated on the PC2. In fact, the average distance from the center 
of metformin-treated control- and c-MYC overexpressing samples 
was 0.60 and 0.43, respectively, on the PC2 axis (arbitrary units-
P > 0.01); Supplementary Table S4). Altogether, these data suggest that 
modulation of the mRNA and protein levels of c-MYC is AMPK- and 
DICER-dependent and relevant for the metabolic anticancer effect 
of metformin. According to a recently published work involving 
mir33a in the regulation of IRS2 mRNA37, we found that metformin 
treatment affected the mRNA and protein levels of IRS2 as well 
(Fig. 7). Additionally, as c-MYC is shown to synergize with HIF1 
alpha to promote aerobic glycolysis and glutaminolysis40,41, we 
tested whether metformin could alter the levels of HIF1alpha. 
This showed that metformin affected significantly the mRNA and 
protein levels of HIF1alpha in hypoxic SUM159PT cells (Fig. 7).
Discussion
Over the last 30 years, metformin has been widely used as an 
antidiabetic agent owing to its relatively mild adverse effects and 
its effective mechanism of action on insulin and glucose levels. 
Recent studies have shown an effect of metformin on tumour-
repopulating cell subpopulations16, and ample epidemiological 
data documented a reduced cancer incidence and cancer mortality 
in metformin-treated diabetic patients11. The molecular relation-
ships between the metabolic and anticancer actions of metformin 
are still poorly defined. In this work, we aimed at investigating a 
mechanistic link between the metabolic action of metformin and its 
anticancer effects. We carried out xenograft transplantation studies, 
and we found that metformin strongly inhibited both the engraft-
ment and re-engraftment of SUM159PT-driven tumours and 
reduced the growth of already established tumours (Fig. 1). Cou-
pling of 1H-NMR metabolic-foot-printing to the xenograft experi-
ments revealed that metformin elicited a number of metabolic 
changes compatible with a clear anticancer effect (Fig. 2). On the 
whole, this consisted of a reversion from the anabolic to the cata-
bolic utilization of glucose, with a significantly reduced utilization 
of glucose for anabolic purposes (for example, nucleotide biosyn-
thesis). In fact, pro-anabolic utilization of carbon-derived glucose 
is a feature of cancer tissues, required to sustain the increased 
requirement for macromolecule biosynthesis42. We set up suit-
able in vitro conditions (for multiple breast cancer cell lines) that 
strictly recapitulated the metabolic changes induced by metformin 
in the xenografted tumours (Supplementary Fig. S2a). This allowed 
us to identify microRNA modulation as an important feature of 
metformin treatment in three breast cancer cell lines differing for 
histological phenotype, p53 status and HER2 expression (MCF-7, 
BT474 and SUM159PT cells) (Supplementary Fig. 2b). Metformin 
was found ineffective in inducing statistically significant changes 
in both the metabolic profile and microRNA expression of dys-
plastic, untransformed MCF10A cells (Supplementary Fig. 2a,b). 
This recalls the absence of any toxic effect we observed in the 
treated mice and pairs with the observation that all the experiments 
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were performed by using non-cytotoxic, clinically relevant concen-
trations of the drug (Supplementary Fig. S1). Metformin surprisingly 
increases the dicer mRNA and protein levels and this is required 
for its anticancer effects in vivo and in vitro (Figs 4 and 5; Sup-
plementary Figs S3 and S4). Cancer cells often exhibit microRNA 
downregulation when compared with their normal counterparts. 
This may be mimicked by the shRNA- or microRNA-mediated 
knockdown of the dicer protein and correlates with the acquisition 
of tumorigenic properties27. Therefore, upregulation of the DICER 
levels by metformin may represent per se an important tumour- 
suppressor mechanism. The overexpression of DICER recapitulated 
largely, but not completely, the effects of the metformin treatment 
(Fig. 5). This suggests that other dicer-independent mechanisms 
may be involved in the action of the drug and it may explain the 
paradoxical downregulation of several microRNAs even in the 
presence of increased levels of dicer in metformin-treated cells 
(Fig. 3b).
Metformin affects the levels of c-MYC and this is mediated by the 
mir33a (Fig. 8). c-MYC is a master regulator of cancer cell metabo-
lism because of its effect on glycolytic and glutaminolytic anabolic 
pathways in cancer cells from various tissues4,5. Overexpression of 
c-MYC renders metformin-treated cells refractory to the metabolic 
effect of the drug, suggesting the functional relevance of c-MYC 
modulation for the effects of metformin (Fig. 6). Metformin treat-
ment affected the levels of HIF1alpha and IRS-2 as well (Fig. 7). IRS-
2 downregulation may be relevant for the interference of metformin 
with the insulin signalling and with cancer cell migration43, and can 
be mediated by the mir-33a43. Additionally, HIF1alpha is known 
to sustain aerobic glycolysis in metastatic cancer cells8,41 and to 
cooperate with c-MYC40. All this unravels metformin’s potential 
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showing the average results of three independent clonogenic (b) or wound healing (c) assays from the indicated sum159PT cells treated as indicated. 
statistics: P < 0.05 by student’s t-test. ns, not significant (d) Tumour volumes (day 55p.i.) of CD1 mice treated with vehicle- or metformin (16 mg kg − 1, 
bi-weekly) before subcutaneous transplantation of the indicated sum159PT cell lines. Tumours with volume >0.1 cm3 were considered as engrafted. The 
engrafted to injected mice ratio is reported for each group. The horizontal bars indicate the mean volume of the engrafted tumours. statistics: P < 0.05 
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in tackling cancer cell metabolism by interfering with cooperative 
mechanisms (Fig. 8). Given that altered metabolism is one of the 
most important characteristics of cancer, we believe this study sug-
gests that a broader use of metabolic modulators such as metformin 
could have a major impact on the treatment of human tumours.
Methods
Reagents. Metformin (1,1-Dimethylbiguanide-hydrochloride) AICAR (5-Ami-
noimidazole-4-carboxamide-1-β-D-ribofuranoside), Phenformin (Phenethylbigua-
nide) and Doxorubicin-hydrochloride were purchased from Sigma-Aldrich.
Cell culture conditions. MCF-7 and BT-474 breast cancer cell lines were grown 
in DMEM/F12 supplemented with 10% non-heat-inactivated FBS (GIBCO); 
SUM159T and MCF10A were grown in DMEM/F12 supplemented with 5% FBS, 
Insulin 5 µg ml − 1 (Sigma) and Hydrocortisone 0.5 µg ml − 1. (Sigma). For cell trans-
fection, Lipofectamine-2000 (Invitrogen) was used, according to manufacturer’s 
instructions.
Cell viability assay. Cell viability was assessed by automated Trypan-Blue exclu-
sion staining (Countess, Invitrogen), according to the manufacturer’s instructions.
Clonogenic assay. Briefly, semiconfluent breast cancer cells were exposed to a 
short pulse of Metformin (0.5 mM per 3 h), and subsequently seeded at 1,000 cells 
per well into 6-well dishes (Costar). Number of colonies was scored by Cristal 
Violet staining 10 days later.
NMR sample preparation. Extracellular metabolites were separated by ultrafiltra-
tion (Amicon). Cell pellets and tissue samples were lyophilized, weighted and cryo-
genically grounded using Cryomill (Retsch GmbH Germany) before methanol/
chloroform/water extraction (2/2/1.8) to extract nonpolar metabolites44,45.
Hydrogen1-nuclear magnetic resonance (1H-NMR) spectroscopy. For the 
Hydrogen-(1H) nuclear magnetic resonance (1H-NMR) analysis, polar extracts 
were dissolved in 600 µl of 1 mM TSP ((trimethylsilyl)-propionic-2,2,3,3-d4 acid) 
and 10 mM NaN3 solution in D2O 0.1 M. phosphate buffer (pH = 7.4), while 
nonpolar extracts were dissolved in 600 µl of CDCl3 containing 0.03% TMS 
(tetramethylsilane)/CD3OD solution (2:1, v/v).
All 2D 1H J-resolved (JRES) NMR spectra were acquired on a 500-MHz 
DRX Bruker Avance spectrometer (Bruker, Germany), using a double spin-echo 
sequence with 8 transients per increment for a total of 32 increments. These were 
collected into 16 k data points using spectral widths of 6 kHz in F2 and 40 Hz in 
F1. There was a 3.0-s relaxation delay. The water resonance was suppressed using 
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Figure 6 | Metformin modulates mir33a and c-MYC levels. (a) qPCR: mir33a levels from the indicated sum159PT-derived cell lines treated as indicated. 
Inset shows the mir-33a binding region. (b) metformin modulates c-mYC-3′uTR activity. 293T cells co-transfected with the c-mYC 3-uTR luciferase 
reporter and either a scrambled- or a specific mir33a-antagonist. Histograms show the normalized luciferase values from three independent experiments. 
(c) qPCR. mRnA levels of c-mYC from the indicated sum159PT-derived cell lines treated as indicated. mean ± s.d. values represent the average of 
three independent experiments. statistics: P < 0.05 by student’s t-test. ns: not significant (d) overexpression of c-mYC attenuates metformin-induced 
metabolic effects. upper panel. WB with anti-c-mYC antibodies of whole cell lysates from sum159PT cells were stably transfected as indicated.  
WB anti-actin as a loading control. Lower panel. 1H-nmR/PCA analysis of the cells as from the upper panel.
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presaturation. Each free induction decay (FID) was Fourier transformed after a 
multiplication with sine-bell window functions in both dimensions. JRES spectra 
were tilted by 45°, symmetrized about F1, referenced to TSP at δH = 0.0 p.p.m. and 
the proton-decoupled skyline projections (p-JRES) exported using Bruker’s XWIN-
NMR software. Metabolites were identified using an in-house NMR database and 
literature data and confirmed by 2D homo- and hetero-nuclear NMR spectroscopy.
31P-NMR spectroscopy. For 31P-NMR analysis nonpolar tissue extracts were 
recovered after the 1H-NMR analysis, N2-dried and redissolved in a mixture of 
CDCl3/CH3OH/0.2 M. aq. K2EDTA (pH = 6.0) (100:29.9:5.2, v/v/v). 31P-NMR 
spectra of nonpolar tissue extracts were obtained at the observation frequency of 
202.5 MHz using a standard Bruker single pulse 1H-decoupled experiment with 
the following parameters: flip- angle of the excitation pulse 60°, acquisition time 
0.82 s, relaxation delay 1.0 s, 2,880 transients. Data processing was performed  
on Lorentz–Gauss transformed spectra with the line broadening of 1.0 Hz.  
1,2-diacyl-sn-glycero-3-phosphocholine was used as chemical-shift reference 
compound ( − 0.84 p.p.m.).
1H and 31P-NMR spectra pre-processing. All p-JRES exported were aligned and 
then reduced into spectral bins with widths ranging from 0.01 to 0.02 p.p.m. by 
using the ACD intelligent bucketing method (ACD/Labs, Canada) that sets the 
bucket divisions at local minima (within the spectra) to ensure that each resonance 
is in the same bin throughout all spectra. After this procedure, the 1H spectra were 
divided into n bins. The area within each spectral bin was integrated to yield an 
n-component vector, where each component value was represented by the integral 
value corresponding to the specific spectral bin. To compare the spectra, the inte-
grals derived from the bucketing procedure were normalized to the total integral 
region, following exclusion of bins corresponding to solvent (residual water/HDO, 
δ 4.76–4.82 p.p.m.; CDCl3, δ 7.45-7.50 p.p.m.; CD3OD, δ 3.33–3.37 p.p.m.), TSP, 
TMS (δ − 0.5 to 0.5 p.p.m.) and metformin peaks (δ 3.03–3.06 p.p.m.). Data from 
extracellular media were expressed in terms of net balances at 0 and 24 h. This was 
done to illustrate the consumption (c) or production (p) of the selected metabolites 
in time. For cell pellets and tissue samples, the data set was constituted by a matrix 
having as rows cell or tissue samples and as columns the integral values of polar 
and nonpolar metabolites determined by 1H- (for cell pellets and tissue samples)  
and 31P-NMR (for tissue samples) spectroscopy.
13C-NMR spectroscopy. For 13C-NMR analysis, cells were incubated for 24 h 
in complete medium containing 3 g l − 1 [1,2-13C2] glucose to obtain an isotopic 
steady-state labelling, and processed as indicated. Phase-sensitive gradient- 
enhanced [13C,1H] HSQC spectra were acquired on a 700-Mhz DRX Bruker 
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Avance spectrometer, with a TCI cryoprobe (Bruker, Germany) with 4 transient 
per increment for a total of 2,000 increments. These were collected into 2 k data 
points using spectral widths of 8 kHz in F2 and 32 kHz in F1. A relaxation delay of 
1.5 s was used. The resulting spectra were processed in Bruker’s Topspin software 
using standard methods.
Statistical analysis. The resulting data was used as input for univariate and multi-
variate analysis PCA34 and OPLS-DA35. PCA and OPLS-DA were conducted using 
SIMCA-P +  version 12 (Umetrics, Umea, Sweden).
Western blotting. The following primary antibodies were used: anti phospho-
AMPKα (Thr-172) (Cell Signaling, #2531); anti-phospho-Raptor (Ser-792) (Cell 
Signaling, #2971); anti-phospho-mTOR(Ser-2448) (Cell Signaling, #2083); anti-
beta actin (A-2228, Sigma); anti c-MYC (Santa Cruz, sc-40), anti-DICER(Santa 
Cruz, sc-30226), anti-HIF1alpha (BD Transduction Laboratories, #610959), 
anti-IRS2 (Cell Signaling, #3089). All the indicated antibodies were used at the 
minimum dilutions suggested by the manufacturer. The Image J software was used 
to quantify the obtained data, according to the manufacturer’s instructions.
RNA processing and hybridization. Total RNA from breast cancer cell lines was 
extracted by TRI Reagent lysis reagent (Ambion), according to manufacturer’s 
instructions. Agilent’s microRNA Complete Labeling and Hyb Kit (Agilent) was 
used to generate fluorescent microRNA, according to manufacturer’s instructions. 
Scanning and image analysis were performed using the Agilent DNA Microarray 
Scanner (P/N G2565BA). Feature Extraction Software (V-10.5) was used for data 
extraction from raw microarray image files using the miRNA_105_Dec-09FE 
protocol.
Statistical analysis. For microRNA analysis, Pearson’s correlation coefficient was 
calculated to assess quality of replicates. ANOVA test (α = 5%) was performed to 
assess statistical significance of the observed differences in microRNA profiling 
(Supplementary Fig. S2). Generally, Student’s t-test was used to assess significance 
of the data whereas the significance of mice survival data was determined by using 
Kaplan–Meier analysis and Mann–Whitney test (Fig. 1b). P-values ≤0.05 were 
considered statistically significant.
MicroRNA analysis. The whole bioinformatic analysis was performed by in-house 
MATLAB scripts. Prediction of the engaged pathways was performed with DIANA 
software (http://diana.cslab.ece.ntua.gr), with manual annotation of the tissue- 
specific pathways. The microarray data can be accessed at http://www.ncbi.nlm.nih.
gov/geo (accession number: GSE37038).
Hypoxia induction. Cells were seeded at 1*106 cells per 60 mm in tissue culture 
glass dishes and grown for 24 h in complete medium. Medium was changed to 
serum-free medium and cells incubated in specially designed glass chambers 
flushed with 5% CO2 and 95% N2. After 24 h, cells were collected and immediately 
processed for further analysis.
Wound healing assay. Briefly, SUM159PT cells were grown to 80% confluence in 
6-well tissue culture plates and wounded with a sterile 10-µl pipette tip to remove 
cells by two perpendicular linear scrapes. The progression of migration was  
photographed at the indicated times.
Xenograft transplantation studies. 4–6 weeks CD1 nude mice (Charles River) 
were subcutaneously transplanted with SUM159PT cells (1×106 cells per mouse) 
and treated as indicated up to the termination of the study. Tumour volume 
(cm3) was calculated as follows: 0.5×D12×D2, where D1 and D2 are the larger and 
smaller diameters measured by caliper. All tumorigenicity assays were carried out 
according to the guidelines set by the Internal Ethical Committee. Necroscopy was 
performed for all the mice at the end of the study by expert pathologists, under 
magnifying glasses.
Immunohistochemistry. Formalin-fixed, paraffin-embedded sections of mice 
tumours were stained with Haematoxylin and Eosin or stained with anti-Ki-67 
antibody (1:200, Ventana, Roche).
Viral infections. Briefly, lentiviral vectors coding for DICER-targeting shRNAs 
were transfected in 293 cells in combination with pMDG and pCMV8.74. to obtain 
viral particles used to infect SUM159PT cells. Psico-DICER (targeting shRNA)  
#1-3 were from Addgene (UK) (plasmids 14763-14764-14765) (Kumar, 2007 
#1736). psicoR-pGK-puro vector (Addgene plasmid-12084) was used as a control 
(Supplementary Fig. S3A). PLKO.1-shRNA#4 was a gift of Dr. Stefano Piccolo 
(Padua, Italy). The scrambled-shRNA consisted of an shRNA insert that contains  
4 base pair mismatches to any known human or mouse gene in the same backbone 
vector (PLKO.1) (SIGMA- SHC002). The DICER RNAi-stable vector (pRRL- 
DICER CDS) was a gift of Dr. Stefano Piccolo.
Luciferase assays. The full length 3′ UTR of the human c-MYC genes were ampli-
fied and inserted downstream of the Renilla luciferase gene into the NotI sites of 
the dual luciferase reporter plasmid PSICHECK-2 (Promega). For 3′-UTR reporter 
assays cells were co-transfected in 24-well plates psiCHECK2-cMyc-3′UTR or 
PSICHECK2 (as a control) together with 40 nM of miR-33a inhibitor or control 
(miRIDIAN, Thermo Scientific-Dharmacon). After 24 h, cells were treated with  
vehicle or metformin and extracts analysed using the Dual Luciferase kit 
(Promega).
Cell-cycle analysis. For cell-cycle analysis, cells were stained 30 min at room tem-
perature (RT) with propidium iodide (50 µg ml − 1 PI, 0.5 mg ml − 1; RNAse in PBS) 
before flow-cytometric analysis.
qPCR. qPCR assays were performed by STEPOne PCR using the FastStart SYBR 
Green Master Mix (Applied Biosytems). Sequences of qPCR primers are DICER 
Fw: 5′-CAAGTGTCAGCTGTCAGAACTC-3′, Rv: 5′-CAATCCACCACAAT 
CTCACATG-3′. IRS-2 Fw 5′-ACGCCAGCATTGACTTCTTGT-3′, Rv :5′-GCCA 
GACAGATCTTCACTCTTTCA-3′ ACTIN Fw: 5′-GGCATGGGTCAGAAG 
GATT-3′, Rv: 5′-CACACGCAGCTCATTGTAGAAG C-MYC-3′ Fw: 5′-CTCCT 
GGCAAAAGGTCAGAG-3′, Rv: 5′-TCGGTTGTTGCTGATCTGTC-3′, HIF1α −  
Fw: 5′-CCCCAGATTCAGGATCAGACA-3′, Rv: 5′-GGACTATTAGGCTCAG 
GTGAACTTTG-3′.
Chromatin immunoprecipitation. Pre-cleared chromatin was incubated overnight 
with the following antibodies: anti-E2F3 (Santa Cruz Biotechnology #251), anti-E2F5 
(Santa Cruz Biotechnology, #999), anti acetylH4 (Upstate #06–866), anti p300(N-15) 
(Santa Cruz Biotechnology, #584), anti-RNA polymerase II CTD(phospho Ser5) 
(Abcam, #5131), anti-Phospho RNA Polymerase II (phospho ser2) (Bethyl #A300-
654A). All the CHIP antibodies were used at 4 micrograms per ml of diluted chroma-
tin. Semiquantitative and quantitative PCR were used to assess for DNA enrichment. 
Primer sequences used (for E2F binding sites: NM_177438) are E2F3 (DICER)Fw: 
5′-TCTGCCAAACTTAGCCGGCCTC-3′, Rv: 5′-GAGCCTGTGATTGGACAG 
GGCCT-3′; E2F5 (DICER)Fw: 5′-GCGGAAGTGGGTGTTTGTTATT-Rv:  
5′-GCGTTTCCTCGCGTTAGTG-3′; cyclin-B1 intron (control) Fw: 5′-
GGAGTCTCTATCGGCTCTTATACCG-3′ Rv: 5′-GTCCAGTTTCCCAAG 
GCCAAT-3′. 
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